Greg Abel’s first quarter as CEO of Berkshire Hathaway signaled a clear shift toward buying whole businesses rather than adding to the stock portfolio—an approach backed by a cash hoard that remains close to historic levels. According to the company’s latest disclosed activity, Abel sold 15 existing stock positions, spent less than $3 billion on new equity purchases (excluding Alphabet), and deployed substantially more capital into acquisitions, including homebuilder Taylor Morrison and chemicals unit OxyChem.
Key takeaways
- Berkshire’s portfolio activity: Abel sold 15 stock holdings and made new equity purchases totaling under $3 billion, while also increasing exposure to Alphabet.
- Largest capital deployment: The company spent $6.8 billion on Taylor Morrison and completed the $9.7 billion OxyChem purchase.
- Cash remains sizable: Berkshire is still sitting on close to $400 billion in cash, leaving room for future deals.
- Implication for investors: The move suggests management may favor operating cash flows from acquired subsidiaries, potentially reducing reliance on market-timing in public stocks.
What drove the shift in Berkshire’s capital allocation
Abel demonstrated a more deal-oriented posture in the first quarter after taking over leadership at the beginning of the year. According to the disclosed transactions, he reduced the stock portfolio by selling 15 positions and focused on concentrating in higher-conviction names.
The company also added two new public-stock positions: Delta Air Lines and Macy’s, with those stakes reported at a combined value of $2.6 billion for Delta Air Lines and $55 million for Macy’s. In addition, Abel tripled Berkshire’s position in Alphabet by adding more than $10 billion of Alphabet stock—although the report notes that Buffett receives credit for the broader Alphabet purchase.
Beyond public markets, Abel’s actions were most pronounced in Berkshire’s acquisition strategy. Since taking office, Berkshire completed two whole-subsidiary purchases. It finished the acquisition of OxyChem from Occidental Petroleum for $9.7 billion in January—a deal that started while Buffett was still CEO—and it acquired homebuilder Taylor Morrison in June for $6.8 billion.
Why whole-business deals may matter more than stock buys now
With nearly $400 billion in cash, Berkshire retains strategic flexibility, but the report frames Abel’s early decisions as prioritizing investments where operating results flow directly into the group’s earnings rather than depending on gains from public-market trading.
According to Buffett’s prior remarks referenced in the report, he and Berkshire have often held back when they do not see attractive opportunities, citing a market environment described as richly valued and influenced by high-multiple themes. The report specifically highlights that some technology-adjacent “AI upstarts” trade at high valuations without profits—an area Berkshire typically would not characterize as aligned with its long-term investment criteria.
In that context, whole-business acquisitions can be viewed as a way to convert cash into durable cash-flow engines that Berkshire can hold for the long term. The report also notes that acquiring subsidiaries reduces certain operational optionality: it may be easier to rotate stock positions for cash than to sell an operating company, which aligns with Berkshire’s preference to buy businesses it can “hold forever” and its tendency to rarely sell subsidiaries.
Market reaction and what shareholders should watch next
Because this item centers on disclosed portfolio moves rather than a contemporaneous earnings report or a guidance change, the immediate market impact would typically be tied less to near-term performance and more to investor confidence in strategy. The first-quarter pattern described in the report—less than $3 billion in new stock buys versus $6.8 billion in a major subsidiary acquisition (and an additional $9.7 billion OxyChem completion)—reinforces a narrative that Berkshire under Abel may keep leaning into concentrated, large-scale deals.
While it is still early to determine whether this becomes a consistent pattern, the approach also fits Berkshire’s broader governance style: capital is deployed selectively, often when attractive assets meet the company’s long-duration underwriting standards.
Investors will likely focus next on whether Berkshire sustains this deal-heavy cadence and how Abel and the board balance public-stock concentration against new acquisition opportunities. Upcoming catalysts include the timing of Berkshire’s next quarterly filings, any additional subsidiary transactions, and—given Berkshire’s sensitivity to valuations and opportunity sets—macro developments that could affect deal pricing and the availability of attractive targets.
